Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
The combination of two nucleoside analogues and one protease inhibitor is a highly active
antiretroviral therapy (HAART) in HIV infected adults. In those with an undetectable viral
load, a once daily combination of FTC, ddI, efavirenz would be easier to take, with less side
effects and the same efficacy. The aim of the study was to evaluate if the once daily
combination presents the same efficacy than the HAART therapy with less side effects and a
better adherence.
Phase:
Phase 3
Details
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis